Key result
Captopril significantly reduced right ventricular weight/tail length ratio (14.9 vs 21.4 mg/cm) and attenuated MMP-2 and MMP-9 expressions in monocrotaline-induced right ventricular hypertrophy.
Why the study?
Does captopril reduce right ventricular hypertrophy and MMP-2/9 expression in a rat model of monocrotaline-induced right ventricular hypertrophy?
Population
Six-week-old male Wistar rats injected intraperitoneally with monocrotaline to induce right ventricular…
Comparison
Captopril administered orally for 24 days from… vs Distilled water administered orally for 24 days.
Design
Preclinical
Follow-up
25 days
Authors
Loading...
Hypothesis-generating for ACE inhibition in experimental RV hypertrophy; clinical translation to pulmonary hypertension remains untested.
Does captopril reduce right ventricular hypertrophy and MMP-2/9 expression in a rat model of monocrotaline-induced right ventricular hypertrophy?
Absolute Event Rate: 14.9% vs 21.4%
p-value: p=<0.05
Captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy and dysfunction in rats, which is associated with the inhibition of MMP-2 and MMP-9.
Okada et al. (2008) studied Monocrotaline-induced right ventricular hypertrophy (n=62). Captopril vs. Monocrotaline alone (vehicle) was evaluated on Right ventricular weight / tail length ratio (p=<0.05). Captopril significantly reduced right ventricular weight/tail length ratio (14.9 vs 21.4 mg/cm) and attenuated MMP-2 and MMP-9 expressions in monocrotaline-induced right ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: